Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro

Thrombosis Research

Volumn 85, Issue 5, 1997, Pages 413-425

  Hansen, John Bjarne ^a   Huseby, K R ^a   Huseby, N E ^a   Ezban, M ^b   Nordoy A ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b NOVO NORDISK A S   (Denmark)

Author keywords

anticoagulant function; LDL; TFPI; Western blotting

Indexed keywords

BLOOD CLOTTING INHIBITOR; LOW DENSITY LIPOPROTEIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL;

ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XA; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MACROMOLECULAR SUBSTANCES; RECOMBINANT PROTEINS;

EID: 0031105294     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00029-7     Document Type: Article

References (39)

1. RAPAPORT S.I., RAO L.V.M. The tissue factor pathway: How it has become a "prima ballerina" Thromb Haemostas. 74:1995;7-17.
2. ØSTERUD B., RAPAPORT S.I. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA. 74:1977;5260-5264.
3. BROZE G.J. Jr., WARREN L.A., NOVOTNY W.F., HIGUCHI D.A., GIRARD J.J., MILETICH J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood. 71:1988;335-343.
4. WARN-CRAMER B.J., RAO L.V.M., MAKI S.L., RAPAPORT S.I. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemostas. 60:1988;453-456.
5. GIRARD T.J., WARREN L.A., NOVOTNY W.F., LIKERT K.M., BROWN S.G., MILETICH J.P., BROZE G.J. Jr. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature. 338:1989;518-520.
6. ABUMIYA T., ENJYOJI K., KOKAWA T., KAMIKUBO Y., KATO H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem. 118:1995;178-182.
7. WESSELSCHMIDT R., LIKERT K.M., GIRARD T.J., WUN T.C., BROZE G.J. Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood. 79:1992;2004-2010.
8. NORFANG O., BJØRN S.E., VALENTIN S., NIELSEN L.S., WILDGOOSE P., BECK T.C., HEDNER U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry. 30:1993;10371-10376.
9. SANDSET P.M., LARSEN M.L., ABILDGAARD U., LINDAHL A.K., ØDEGAARD O.R. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 2:1991;425-433.
10. SANDSET P.M., LUND H., NORSETH J., ABILDGAARD U., OSE L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb. 11:1991;138-145.
11. HANSEN J.B., HUSEBY N.E., SANDSET P.M., SVENSSON B., LYNGMO V., NORDØY A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 14:1994;223-229.
12. HANSEN J.B., HUSEBY K.R., HUSEBY N.E., SANDSET P.M., HANSEN T.A., NORDØY A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol. 15:1995;879-885.
13. ABUMIYA T., NAKAMURA S., TAKENAKA A., TAKENAKA O., YOSHIKUNI Y., MIYAMOTO S., KIMURA T., ENJYOJI K.I., KATO H. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler Thromb. 14:1994;483-488.
14. PRYDZ, H. The tissue factor pathway and cardiovascular disease. In Atherosclerotic cardiovascular disease, hemostasis and endothelial function: Fundamental and clinical cardiology, volume 8. R.B., Francis Jr., editor. New York, NY: Marcel Dekker, Inc. pp. 35-52, 1992.
15. WILCOX J.N., SMITH K.M., SCHWARTZ S.M., GORDON D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 86:1989;2839-2843.
16. DAVIES M.J., WOOLF N. Atherosclerosis: What is it and why does it occur? Br Heart J. 69:(suppl):1993;S3-S11.
17. HJORT P.F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest. 9:(suppl 27):1957;1-173.
18. PEDERSEN A.H., NORFANG O., NORRIS F., WIBERG F.C., CHRISTENSEN M., MOELLER K.B., MEIDAHL-PEDERSEN J., BECK T.C., NORRIS K., HEDNER U., KISIEL W. Recombinant human extrinsic pathway inhibitor: Production, isolation and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem. 265:1990;16786-16793.
19. LITSKE PETERSEN J.G., MEYN G., RASMUSSEN J.S., PETERSEN J., BJØRN S.E., JONASSEN I., CHRISTIANSEN L., NORFANG O. Characterization of human tissue factor pathway inhibitor variants expressed in saccharomyces cerevisiae. J Biol Chem. 268:1993;13344-13351.
20. ERHARDSEN E., EZBAN M., MADSEN M.T., DINESS V., GLAZER S., HEDNER U., NORFANG O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis. 6:1995;388-395.
21. MCKINNEY M.M., PARKINSON A. A simple, non-chromatographic procedure to purity immunoglobulins from serum and ascites fluid. J Immunol Methods. 96:1987;271-278.
22. KASPER C.K., ALEDORF M.L., COUNTS R.B., EDSON J.R., FRATANTONI J., GREEN D., HAMPTON J.W., HILGARTNER M.W., LAZERSON J., LEVINE P.H., MCMILLAN C.W., POOL J.G., SHAPIRO S.S., SHULMAN N.R., VAN EYS J. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes haemorrh. 34:1975;869-872.
23. BROZE G.J. Jr., LANGE G.W., DUFFIN K.L., MACPHAIL L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 5:1994;551-559.
24. REDGRAVE T.G., ROBERTS D.C.K., WEST C.E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 65:1975;42-49.
25. EL-SAADANI M., ESTERBAUER H., EL-SAYED M., GOHER M., NASSAR A.Y., JURGENS G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lip Res. 30:1989;627-630.
26. LAEMMLI U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
27. NOVOTNY W.F., BROWN S.G., MILETICH J.P., RADER D.J., BROZE G.J. Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 78:1991;387-393.
28. LINDAHL A.K., JACOBSEN P.B., SANDSET P.M., ABILDGAARD U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 2:1991;713-721.
29. SANDSET P.M., ABILDGAARD U., LARSEN M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 50:1988;803-813.
30. NOVOTNY W.F., PALMIER M., WUN T.C., BROZE G.J. Jr., MILETICH J.P. Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood. 78:1991;394-400.
31. LINDAHL A.K., ABILDGAARD U., STAALESEN R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res. 64:1991;155-168.
32. LINDAHL A.K., SANDSET P.M., ABILDGAARD U., ANDERSSON T.R., HARBITZ T.B. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand. 155:1989;389-393.
33. NOVOTNY W.F., GIRARD T.J., MILETICH J.P., BROZE G.J. Jr. Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma. J Biol Chem. 264:1989;18831-18837.
34. LINDAHL A.K., ABILDGAARD U., LARSEN M.L., STAALESEN R., HAMMER A.K.G., SANDSET P.M., NORFANG O., BECK T.C. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res. 62:1991;607-614.
35. VALENTIN, S., NORDFANG, O., BREGENGAARD, C. and WILDGOOSE, P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 4, 713-20, 1993.
36. 1-161) in experimental venous thrombosis: a comparison with low molecular weight heparin. Thromb Haemostas. 71:1994;214-219.
37. LINDAHL, A.K., NORDFANG, O., WILDGOOSE, P., KELLY, A.B., HARKER, L.A., HANSON, S.R. Antithrombotic effects of a truncated tissue factor pathway inhibitor in baboons. Thromb Haemostas 69, 742 (abstract), 1993.
38. HOLST J., LINDBLAD B., WESTERLUND G., BREGENGAARD C., EZBAN M., ØSTERGAARD P.B., NORDFANG O., HEDNER U. Pharmacokinetics and delayed experimental antithrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor. Thromb Res. 81:1996;461-470.
39. LINDAHL A.K., SANDSET P.M., ABILDGAAR U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 3:1992;439-449.